{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:40:26Z","timestamp":1773294026199,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029219","name":"Patterson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032148","name":"Biohaven Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaac.2024.10.011","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T20:08:09Z","timestamp":1730664489000},"page":"577-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette\u2019s Disorder Medications"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-876X","authenticated-orcid":false,"given":"Pedro","family":"Macul Ferreira de Barros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-8344","authenticated-orcid":false,"given":"Luis C.","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-447X","authenticated-orcid":false,"given":"Emily","family":"Behling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeeha","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-6132","authenticated-orcid":false,"given":"Angeli","family":"Landeros-Weisenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-4080","authenticated-orcid":false,"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2024.10.011_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114684","article-title":"Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States","volume":"314","author":"Tinker","year":"2022","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.jaac.2024.10.011_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10578-010-0211-4","article-title":"Exploring the impact of chronic tic disorders on youth: results from the Tourette Syndrome Impact Survey","volume":"42","author":"Conelea","year":"2011","journal-title":"Child Psychiatry Hum Dev"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10597-011-9465-y","article-title":"The impact of Tourette syndrome in adults: results from the Tourette Syndrome Impact Survey","volume":"49","author":"Conelea","year":"2013","journal-title":"Community Ment Health J"},{"issue":"19","key":"10.1016\/j.jaac.2024.10.011_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jaac.2024.10.011_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaac.2013.09.015","article-title":"Practice parameter for the assessment and treatment of children and adolescents with tic disorders","volume":"52","author":"Murphy","year":"2013","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2024.10.011_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113400","article-title":"Treatment use among children with Tourette syndrome living in the United States, 2014","volume":"293","author":"Wolicki","year":"2020","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.jaac.2024.10.011_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S2352-4642(22)00316-9","article-title":"Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette\u2019s syndrome: a systematic review and network meta-analysis","volume":"7","author":"Farhat","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"10.1016\/j.jaac.2024.10.011_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi","year":"2020","journal-title":"World Psychiatry"},{"issue":"12","key":"10.1016\/j.jaac.2024.10.011_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/mp.2012.105","article-title":"Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?","volume":"17","author":"Kapur","year":"2012","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.biopsych.2017.05.025","article-title":"The roles of phasic and tonic dopamine in tic learning and expression","volume":"82","author":"Maia","year":"2017","journal-title":"Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.jaac.2024.10.011_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28204","article-title":"Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial","volume":"4","author":"Jankovic","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.jaac.2024.10.011_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.29397","article-title":"Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome: a randomized clinical trial","volume":"4","author":"Coffey","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaac.2024.10.011_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","article-title":"Deutetrabenazine in tics associated with Tourette syndrome","volume":"6","author":"Jankovic","year":"2016","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib14","first-page":"9","article-title":"Tetrabenazine in the treatment of Tourette syndrome","volume":"5","author":"Kenney","year":"2007","journal-title":"J\u00a0Pediatr Neurol"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib15","first-page":"4518","article-title":"Real-world experience with VMAT2 inhibitors in Tourette syndrome","volume":"270","author":"Makhoul","year":"2023","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000490354","article-title":"Implications of placebo and nocebo effects for clinical practice: expert consensus","volume":"87","author":"Evers","year":"2018","journal-title":"Psychother Psychosom"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jocrd.2014.03.004","article-title":"Clinical features of Tourette syndrome and tic disorders","volume":"3","author":"Leckman","year":"2014","journal-title":"J\u00a0Obsessive Compuls Relat Disord"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.25365","article-title":"Impact of placebo assignment in clinical trials of tic disorders: placebo in tic disorders","volume":"28","author":"Cubo","year":"2013","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","article-title":"Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study","volume":"25","author":"Cummings","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"10.1016\/j.jaac.2024.10.011_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A\u00a0placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial","volume":"64","author":"M\u00fcller-Vahl","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2024.10.011_bib93","unstructured":"J.P.T. Higgins, J. Thomas, J. Chandler, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.training.cochrane.org\/handbook"},{"key":"10.1016\/j.jaac.2024.10.011_bib94","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.jaac.2024.10.011_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","article-title":"Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13229-020-00372-z","article-title":"Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis","volume":"11","author":"Siafis","year":"2020","journal-title":"Mol Autism"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41380-021-01134-w","article-title":"Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis","volume":"27","author":"Faraone","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2024.10.011_bib25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","article-title":"Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jaac.2024.10.011_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mds.26891","article-title":"Systematic review of severity scales and screening instruments for tics: critique and recommendations","volume":"32","author":"Martino","year":"2017","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jaac.2024.10.011_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jclinepi.2013.03.009","article-title":"Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study","volume":"66","author":"da Costa","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaac.2024.10.011_bib28","article-title":"Choosing effect measures and computing estimates of effect","author":"Higgins","year":"2022"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaac.2024.10.011_bib30","article-title":"Including variants on randomized trials","author":"Higgins","year":"2022"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S2045796016000809","article-title":"Pre-post effect sizes should be avoided in meta-analyses","volume":"26","author":"Cuijpers","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/biostatistics\/kxm023","article-title":"An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown","volume":"9","author":"Riley","year":"2008","journal-title":"Biostatistics"},{"key":"10.1016\/j.jaac.2024.10.011_bib33","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jaac.2024.10.011_bib34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"7109","key":"10.1016\/j.jaac.2024.10.011_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jaac.2024.10.011_bib36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"7","key":"10.1016\/j.jaac.2024.10.011_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Losing participants before the trial ends erodes credibility of findings","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatr Bull"},{"issue":"10327","key":"10.1016\/j.jaac.2024.10.011_bib38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"3","key":"10.1016\/j.jaac.2024.10.011_bib40","first-page":"1","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.jaac.2024.10.011_bib41","article-title":"metamisc: Meta-Analysis of Diagnosis and Prognosis Research Studies","author":"Debray","year":"2022","journal-title":"R package version 0.4.0"},{"issue":"12","key":"10.1016\/j.jaac.2024.10.011_bib42","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","article-title":"Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders","volume":"65","author":"Allen","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2015.0109","article-title":"N-acetylcysteine in the treatment of pediatric Tourette syndrome: randomized, double-blind, placebo-controlled add-on trial","volume":"26","author":"Bloch","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2024.10.011_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00004583-199705000-00008","article-title":"Controlled stimulant treatment of ADHD and comorbid Tourette\u2019s syndrome: effects of stimulant and dose","volume":"36","author":"Castellanos","year":"1997","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","article-title":"Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders","volume":"42","author":"Du","year":"2008","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.46.4.965","article-title":"A\u00a0controlled trial of deprenyl in children with Tourette\u2019s syndrome and attention deficit hyperactivity disorder","volume":"46","author":"Feigin","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib48","doi-asserted-by":"crossref","first-page":"e1493","DOI":"10.1542\/peds.2011-3384","article-title":"A\u00a0double-blind, placebo-controlled trial of \u03c9-3 fatty acids in Tourette\u2019s disorder","volume":"129","author":"Gabbay","year":"2012","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.jaac.2024.10.011_bib49","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/chi.0b013e31805c0860","article-title":"Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder","volume":"46","author":"Gadow","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib50","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.54.6.1310","article-title":"Tourette\u2019s syndrome improvement with pergolide in a randomized, double-blind, crossover trial","volume":"54","author":"Gilbert","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1212\/01.WNL.0000044058.64647.7E","article-title":"Tic reduction with pergolide in a randomized controlled trial in children","volume":"60","author":"Gilbert","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jaac.2024.10.011_bib52","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","article-title":"Ecopipam, a D1 receptor antagonist, for treatment of Tourette syndrome in children: a randomized, placebo-controlled crossover study","volume":"33","author":"Gilbert","year":"2018","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jaac.2024.10.011_bib53","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-059574","article-title":"Ecopipam for Tourette syndrome: a randomized trial","volume":"151","author":"Gilbert","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2024.10.011_bib54","first-page":"668","article-title":"A\u00a0pilot study of levodopa for treatment of tics in children and adults","volume":"4","author":"Gordon","year":"2008","journal-title":"F1000Posters"},{"key":"10.1016\/j.jaac.2024.10.011_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115098","article-title":"Effects of Yi-Gan-san on the psychiatric behavior of children and adolescents with Tourette\u2019s syndrome: a randomized, double-blind, controlled preliminary study","volume":"290","author":"Huang","year":"2022","journal-title":"J\u00a0Ethnopharmacol"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","article-title":"A\u00a0randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","author":"Jankovic","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mds.24919","article-title":"A\u00a0multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette\u2019s syndrome","volume":"27","author":"Kurlan","year":"2012","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","article-title":"Clonidine treatment of Gilles de la Tourette\u2019s syndrome","volume":"48","author":"Leckman","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pediatrneurol.2015.02.002","article-title":"Efficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of D-serine and riluzole in Tourette syndrome","volume":"52","author":"Lemmon","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib60","first-page":"426","article-title":"Xifeng zhidong tablet and the placebo control treatment of tic disorder children patients of internal disturbance of Gan-wind with phlegm syndrome: a clinical study","volume":"34","author":"Ma","year":"2014","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib61","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300012","article-title":"Tetrahydrocannabinol and cannabidiol in Tourette syndrome","volume":"2","author":"Mosley","year":"2023","journal-title":"NEJM Evid"},{"issue":"10","key":"10.1016\/j.jaac.2024.10.011_bib62","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/mds.28681","article-title":"Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study","volume":"36","author":"M\u00fcller-Vahl","year":"2021","journal-title":"Mov Disord"},{"key":"10.1016\/j.jaac.2024.10.011_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115135","article-title":"CANNA-TICS: efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders\u2014results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study","volume":"323","author":"M\u00fcller-Vahl","year":"2023","journal-title":"Psychiatry Res"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib64","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/cap.2017.0024","article-title":"Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders","volume":"27","author":"Murphy","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.jaac.2024.10.011_bib65","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/01.chi.0000163279.39598.44","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette\u2019s disorder","volume":"44","author":"Nicolson","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.jaac.2024.10.011_bib66","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","article-title":"Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder","volume":"154","author":"Sallee","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2024.10.011_bib67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib68","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/cap.2016.0026","article-title":"Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents","volume":"27","author":"Sallee","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2024.10.011_bib69","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/cap.1997.7.75","article-title":"Fluoxetine has no marked effect on tic symptoms in patients with Tourette\u2019s syndrome: a double-blind placebo-controlled study","volume":"7","author":"Scahill","year":"1997","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.jaac.2024.10.011_bib70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A\u00a0placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jaac.2024.10.011_bib71","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","article-title":"Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette\u2019s syndrome","volume":"46","author":"Shapiro","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2024.10.011_bib72","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","article-title":"Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette\u2019s disorder","volume":"40","author":"Silver","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2024.10.011_bib73","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","article-title":"Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial","volume":"56","author":"Singer","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jaac.2024.10.011_bib74","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/mds.21615","article-title":"A\u00a0double blind randomized placebo control trial of levetiracetam in Tourette syndrome","volume":"22","author":"Smith-Hicks","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.jaac.2024.10.011_bib75","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.59.7.649","article-title":"A\u00a0double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit\/hyperactivity disorder","volume":"59","author":"Spencer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib76","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jaac.2024.10.011_bib77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4088\/JCP.v66n0413","article-title":"Ondansetron treatment in Tourette\u2019s disorder: a 3-week, randomized, double-blind, placebo-controlled study","volume":"66","author":"Toren","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"16","key":"10.1016\/j.jaac.2024.10.011_bib78","first-page":"3100","article-title":"Efficacy and safety of Choudongning capsule (CDN) in children with Tourette\u2019s syndrome of spleen deficiency and phlegm accumulation","volume":"41","author":"Yang","year":"2016","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"8","key":"10.1016\/j.jaac.2024.10.011_bib79","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.4088\/JCP.12m08189","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder","volume":"74","author":"Yoo","year":"2013","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib80","first-page":"169","article-title":"Traditional Chinese medicine Ningdong granule: the beneficial effects in Tourette\u2019s disorder","volume":"38","author":"Zhao","year":"2010","journal-title":"J\u00a0Int Med Res"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jcpp.12432","article-title":"A\u00a0proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial","volume":"57","author":"Zheng","year":"2016","journal-title":"J\u00a0Child Psychol Psychiatry"},{"issue":"1572","key":"10.1016\/j.jaac.2024.10.011_bib83","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1098\/rstb.2010.0384","article-title":"The placebo response in clinical trials: more questions than answers","volume":"366","author":"Enck","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"3","key":"10.1016\/j.jaac.2024.10.011_bib82","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mds.29714","article-title":"Placebo and nocebo responses in pharmacological trials of tic disorders: a meta-analysis","volume":"39","author":"Wang","year":"2024","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.jaac.2024.10.011_bib84","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1089\/cap.2021.0030","article-title":"Meta-analysis: pediatric placebo response in depression trials does not replicate in anxiety and obsessive-compulsive disorder trials","volume":"31","author":"Nasir","year":"2021","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2024.10.011_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2022.05.023","article-title":"Large variation existed in standardized mean difference estimates using different calculation methods in clinical trials","volume":"149","author":"Luo","year":"2022","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaac.2024.10.011_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02638-x","article-title":"Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: an umbrella review","author":"Huenke","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib87","first-page":"1","article-title":"Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy","volume":"21","author":"Furukawa","year":"2018","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamapsychiatry.2021.3204","article-title":"Association of single-blind placebo run-in periods with the placebo response in randomized clinical trials of antidepressants: a systematic review and meta-analysis","volume":"79","author":"Scott","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2024.10.011_bib89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/2046-4053-2-107","article-title":"Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis","volume":"2","author":"Hempel","year":"2013","journal-title":"Syst Rev"},{"issue":"1","key":"10.1016\/j.jaac.2024.10.011_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/wps.21056","article-title":"The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents","volume":"22","author":"Correll","year":"2023","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2024.10.011_bib91","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/cap.2010.0149","article-title":"Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale","volume":"21","author":"Storch","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2024.10.011_bib92","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856724019737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856724019737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:50:00Z","timestamp":1762314600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856724019737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0890856724019737"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2024.10.011","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette\u2019s Disorder Medications","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2024.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92024 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}